Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial

被引：0

作者：

Waidmann, O. ^{[1
]}

Abou-Alfa, G. K. ^{[2
]}

Meyer, T. ^{[3
]}

Cheng, A-L ^{[4
]}

El-Khoueiry, A. B. ^{[5
]}

Rimassa, L. ^{[6
]}

Ryoo, B-Y ^{[7
]}

Cicin, I ^{[8
]}

Merle, P. ^{[9
]}

Chen, Y. H. ^{[10
]}

Park, J-W ^{[11
]}

Blanc, J-F ^{[12
]}

Bolondi, L. ^{[13
]}

Klumpen, H-J ^{[14
]}

Chan, S. L. ^{[15
]}

Dadduzio, V ^{[16
]}

Hessel, C. ^{[17
]}

Borgman-Hagey, A. E. ^{[17
]}

Schwab, G. ^{[17
]}

Kelley, R. K. ^{[18
]}

机构：

[1] Univ Liver & Canc Ctr Frankfurt, Frankfurt, Germany

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Royal Free Hosp, London, England

[4] Natl Taiwan Univ Hosp, Taipei, Taiwan

[5] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA

[6] Humanitas Canc Ctr, Humanitas Clin & Res Ctr, Rozzano, Italy

[7] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[8] Trakya Univ, Sch Med, Edirne, Turkey

[9] Groupement Hosp Lyon Nord, Lyon, France

[10] Liou Ying ChiMei Hosp, Dept Med Oncol, Tainan, Taiwan

[11] Natl Canc Ctr, Goyang, South Korea

[12] CHU, Hop Haut Leveque, Bordeaux, France

[13] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy

[14] Univ Amsterdam, Dept Med Oncol, Acad Med Ctr, Amsterdam, Netherlands

[15] Chinese Univ Hong Kong, State Key Lab Oncol South China, Hong Kong, Hong Kong, Peoples R China

[16] UOC, Ist Oncol Veneto, IRCCS, Padua, Italy

[17] Exelixis Inc, San Francisco, CA USA

[18] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V763

引用

页码：254 / 254

页数：1

共 50 条

[31] Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
Cainap, Calin
Qin, Shukui
Huang, Wen-Tsung
Chung, Ik-Joo
Pan, Hongming
Cheng, Ying
Kudo, Masatoshi
Kang, Yoon-Koo
Chen, Pei-Jer
Toh, Han Chong
Gorbunova, Vera
Eskens, Ferry
Qian, Jiang
McKee, Mark D.
Ricker, Justin L.
Carlson, Dawn M.
El Nowiem, Saied
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
[32] Association of adverse events (AEs) with efficiacy outcomes for Cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase 3 CELESTIAL trial
Trojan, J.
Abou-Alfa, G. K.
Meyer, T.
Cheng, A. -L.
Cicin, I.
Bolondi, L.
Kluempen, H. J.
Chan, S. L.
Dadduzio, V.
Milwee, S.
Dubey, S.
Kelley, R. K.
El-Khoueiry, A. B.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 243 - 243
[33] Association of Adverse Events (AES) with Efficiacy Outcomes for Cabozantinib (C) in Patients (PTS) with Advanced Hepatocellular Carcinoma (AHCC) in the Phase 3 Celestial Trial
Waidmann, Oliver
Abou-Alfa, G. K.
Meker, T.
Cheng, A. L.
Cicin, I.
Bolondi, L.
Klumpem, H. J.
Chan, S. L.
Dadduzio, V.
Milwee, S.
Dubey, S.
Kelley, R. K.
El-Khoueiry, A. B.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 60 - 60
[34] BRIVANIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) WHO FAILED OR WERE INTOLERANT TO SORAFENIB: RESULTS FROM THE PHASE 3 BRISK-PS STUDY
Llovet, J. M.
Decaens, T.
Raoul, J. -L.
Boucher, E.
Kudo, M.
Chang, C.
Kang, Y. -K.
Assenat, E.
Lim, H. -Y.
Boige, V.
Mathurin, P.
Fartoux, L.
Lin, D. -Y.
Bruix, J.
Poon, R. T.
Sherman, M.
Blanc, J. -F.
Finn, R.
Tak, W. -Y.
Chao, Y.
Ezzeddine, R.
Liu, D.
Walters, I.
Park, J. -W.
JOURNAL OF HEPATOLOGY, 2012, 56 : S549 - S549
[35] Outcomes based on Albumin-Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellulat carcinoma (HCC)
Miksad, R.
Cicin, I.
Chen, Y.
Klumpen, H.
Kim, S.
Lin, Z.
Youkstetter, J.
Sen, S.
Cheng, A.
Meyer, T.
Kelley, R.
Abou-Alfa, G.
ANNALS OF ONCOLOGY, 2019, 30 : 134 - 134
[36] Phase II trial of tepotinib vs sorafenib in Asian patients (pts) with advanced hepatocellular carcinoma (HCC)
Ryoo, B-Y.
Ren, Z.
Kim, T-Y.
Pan, H.
Rau, K-M.
Choi, H. J.
Park, J-W.
Kim, J. H.
Yen, C-J.
Kim, B-H.
Zhou, D.
Straub, J.
Zhao, C.
Qin, S.
ANNALS OF ONCOLOGY, 2018, 29
[37] First stage results of a phase II trial of sorafenib plus doxorubicin (SD) in patients (pts) with advanced hepatocellular carcinoma (HCC) who progressed (POD) on sorafenib (S)
Abou-Alfa, Ghassan K.
Capanu, Marinela
Do, Richard Kinh Gian
Hollywood, Ellen
Ly, Michele
Chou, Joanne F.
Lee, Jean Kyung
Connell, Louise Catherine
Wan, Peter Justin
Bradley, Margaret
Harding, James J.
Saltz, Leonard
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[38] METEOR: results from the randomized phase 3 trial of cabozantinib versus everolimus in pts with advanced renal cell carcinoma (RCC)
Powles, Thomas
Escudier, Bernard
Mainwaring, Paul N.
Rini, Brian I.
Donskov, Frede
Hammers, Hans J.
Hutson, Thomas E.
Roth, Bruce
Peltola, Katriina
Lee, Jae Lyun
Heng, Daniel Y. C.
Schmidinger, Manuela
Borgman, Anne
Hessel, Colin
Scheffold, Christian
Schwab, Gisela
Tannir, Nizar M.
Motzer, Robert J.
Choueiri, Toni K.
BJU INTERNATIONAL, 2015, 116 : 19 - 19
[39] Assessment of tumor response, alpha-fetoprotein (AFP) response, and time to progression (TTP) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
Yau, T.
Merle, P.
Rimassa, L.
Ryoo, B-Y.
Cicin, I.
Harris, W. P.
Banu, E.
Sarker, D.
Tan, B.
van Vlierberghe, H.
Sen, S.
Love, C.
Cheng, A-L.
Meyer, T.
Kelley, R. K.
Abou-Alfa, G. K.
ANNALS OF ONCOLOGY, 2018, 29
[40] Randomized phase II trial comparing the efficacy and safety of nintedanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
Palmer, Daniel H.
Ma, Yuk Ting
Peck-Radosavljevic, Markus
Ross, Paul J.
Graham, Janet Shirley
Fartoux, Laetitia
Deptala, Andrzej
Wenz, Arne
Hocke, Julia
Loembe, Arsene-Bienvenu
Meyer, Tim
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)

← 1 2 3 4 5 →